A phase 2 randomized, double-blind, placebo-controlled study of tremelimumab for second and third line treatment in patients with unresectable pleural or peritoneal mesothelioma

Overview of attention for article published in Journal for Immunotherapy of Cancer, November 2013

Altmetric Badge

Citations

So far, Dimensions has found 1 citation of this research output.

The most recent citing publication is shown below. View this citation on Dimensions.

Article in Expert Opinion on Investigational Drugs (September 2014)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.